Early Growth Response 3 regulates genes of inflammation and directly activates IL6 and IL8 expression in prostate cancer

British Journal of Cancer

Volumn 112, Issue 4, 2015, Pages 755-764

  Baron, V T ^a   Pio, R ^b   Jia, Z ^b,c,d   Mercola, D ^b  

^a Vaccine Research Institute of San Diego   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF AKRON   (United States)

^d Northeast Ohio Medical University   (United States)

Author keywords

EGR3; IL6; IL8; inflammation; NF B; prostate cancer

Indexed keywords

EARLY GROWTH RESPONSE FACTOR 3; GROWTH FACTOR; INTERLEUKIN 6; INTERLEUKIN 8; SHORT HAIRPIN RNA; EGR3 PROTEIN, HUMAN; IL6 PROTEIN, HUMAN; IL8 PROTEIN, HUMAN;

ARTICLE; BINDING SITE; CANCER CELL; CHROMATIN IMMUNOPRECIPITATION; CHRONIC INFLAMMATION; CONTROLLED STUDY; GAIN OF FUNCTION MUTATION; GENE; GENE CONTROL; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; MALE; NON-TRANSFORMED CELL; PRIORITY JOURNAL; PROSTATE CANCER; REAL TIME POLYMERASE CHAIN REACTION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; INFLAMMATION; MICROARRAY ANALYSIS; PHYSIOLOGY; PROSTATE TUMOR; TRANSCRIPTION INITIATION; TUMOR CELL CULTURE;

EARLY GROWTH RESPONSE PROTEIN 3; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INFLAMMATION; INTERLEUKIN-6; INTERLEUKIN-8; MALE; MICROARRAY ANALYSIS; PROSTATIC NEOPLASMS; TRANSCRIPTIONAL ACTIVATION; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 84923598439     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.622     Document Type: Article

References (48)

1. Bae VL, Jackson-Cook CK, Maygarden SJ, Plymate SR, Chen J, Ware JL. (1998). Metastatic sublines of an SV40 large T antigen immortalized human prostate epithelial cell line. Prostate 34: 275-282
2. Balkwill F, Charles KA, Mantovani A. (2005). Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7: 211-217
3. Balkwill FR, Mantovani A. (2012). Cancer-related inflammation: common themes and therapeutic opportunities. Semin Cancer Biol 22: 33-40
4. Bardia A, Platz EA, Yegnasubramanian S, De Marzo AM, Nelson WG. (2009). Anti-inflammatory drugs, antioxidants, and prostate cancer prevention. Curr Opin Pharmacol 9: 419-426
5. Ben-Baruch A. (2006). Inflammation-associated immune suppression in cancer: the roles played by cytokines, chemokines and additional mediators. Semin Cancer Biol 16: 38-52
6. Brawley OW. (2012). Prostate cancer epidemiology in the United States. World J Urol 30: 195-200
7. Chan JM, Feraco A, Shuman M, Hernandez-Diaz S. (2006). The epidemiology of prostate cancer-with a focus on nonsteroidal anti-inflammatory drugs. Hematol Oncol Clin North Am 20: 797-809
8. Culig Z, Puhr M. (2012). Interleukin-6: a multifunctional targetable cytokine in human prostate cancer. Mol Cell Endocrinol 360: 52-58
9. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, Drake CG, Nakai Y, Isaacs WB, Nelson WG. (2007). Inflammation in prostate carcinogenesis. Nat Rev 7: 256-269
10. De Nunzio C, Kramer G, Marberger M, Montironi R, Nelson W, Schroder F, Sciarra A, Tubaro A. (2011). The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation. Eur Urol 60: 106-117
11. De Visser KE, Korets LV, Coussens LM. (2005). De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 7: 411-423
12. Giri D, Ozen M, Ittmann M. (2001). Interleukin-6 is an autocrine growth factor in human prostate cancer. Am J Pathol 159: 2159-2165
13. Gitenay D, Baron VT. (2009). Is EGR1 a potential target for prostate cancer therapy?. Future Oncol 5: 993-1003
14. Gomez-Martin D, Diaz-Zamudio M, Galindo-Campos M, Alcocer-Varela J. (2010). Early growth response transcription factors and the modulation of immune response: implications towards autoimmunity. Autoimmun Rev 9: 454-458
15. Grivennikov SI, Greten FR, Karin M. (2010). Immunity, inflammation, and cancer. Cell 140: 883-899
16. Gurel B, Lucia MS, Thompson Jr IM, Goodman PJ, Tangen CM, Kristal AR, Parnes HL, Hoque A, Lippman SM, Sutcliffe S, Peskoe SB, Drake CG, Nelson WG, De Marzo AM, Platz EA. (2014). Chronic inflammation in benign prostate tissue is associated with high-grade prostate cancer in the placebo arm of the Prostate Cancer Prevention Trial. Cancer Epidemiol Biomarkers Prev 23: 847-856
17. Hanahan D, Weinberg RA. (2011). Hallmarks of cancer: the next generation. Cell 144: 646-674
18. Harris RE. (2009). Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung. Inflammopharmacology 17: 55-67
19. Huang da W, Sherman BT, Lempicki RA (2009a) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4: 44-57
20. Huang da W, Sherman BT, Zheng X, Yang J, Imamichi T, Stephens R, Lempicki RA (2009b) Extracting biological meaning from large gene lists with DAVID. Curr Protoc Bioinformatics Chapter 13: Unit 13.11
21. Inoue A, Omoto Y, Yamaguchi Y, Kiyama R, Hayashi SI. (2004). Transcription factor EGR3 is involved in the estrogen-signaling pathway in breast cancer cells. J Mol Endocrinol 32: 649-661
22. Kanterman J, Sade-Feldman M, Baniyash M. (2012). New insights into chronic inflammation-induced immunosuppression. Semin Cancer Biol 22: 307-318
23. Karin M. (2009). NF-kappaB as a critical link between inflammation and cancer. Cold Spring Harb Perspect Biol 1: a000141
24. Kim R, Emi M, Tanabe K. (2007). Cancer immunoediting from immune surveillance to immune escape. Immunology 121: 1-14
25. Lewis CE, Pollard JW. (2006). Distinct role of macrophages in different tumor microenvironments. Cancer Res 66: 605-612
26. Liao F, Ji MY, Shen L, Qiu S, Guo XF, Dong WG. (2013). Decreased EGR3 expression is related to poor prognosis in patients with gastric cancer. J Mol Histol 44: 463-468
27. Lin EY, Pollard JW. (2004). Role of infiltrated leucocytes in tumour growth and spread. Br J Cancer 90: 2053-2058
28. Mantovani A, Germano G, Marchesi F, Locatelli M, Biswas SK. (2012). Cancer-promoting tumor-associated macrophages: new vistas and open questions. Eur J Immunol 41: 2522-2525
29. Mittal D, Gubin MM, Schreiber RD, Smyth MJ. (2014). New insights into cancer immunoediting and its three component phases-elimination, equilibrium and escape. Curr Opin Immunol 27C: 16-25
30. Nozawa H, Chiu C, Hanahan D. (2006). Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proc Natl Acad Sci USA 103: 12493-12498
31. Perez-Cadahia B, Drobic B, Davie JR. (2011). Activation and function of immediate-early genes in the nervous system. Biochem Cell Biol 89: 61-73
32. Pio R, Jia Z, Baron VT, Mercola D. (2013). Early growth response 3 (Egr3) is highly over-expressed in non-relapsing prostate cancer but not in relapsing prostate cancer. PLoS One 8: e54096
33. Plymate SR, Tennant M, Birnbaum RS, Thrasher JB, Chatta G, Ware JL. (1996). The effect on the insulin-like growth factor system in human prostate epithelial cells of immortalization and transformation by simian virus-40 T antigen. J Clin Endocrinol Metabol 81: 3709-3716
34. Pruthi RS, Wallen EM. (2005). Cyclooxygenase-2: a therapeutic target for prostate cancer. Clin Genitourin Cancer 4: 203-211
35. Rasmussen LM, Frederiksen KS, Din N, Galsgaard E, Christensen L, Berchtold MW, Panina S. (2010). Prolactin and oestrogen synergistically regulate gene expression and proliferation of breast cancer cells. Endocr Relat Cancer 17: 809-822
36. Rojas A, Liu G, Coleman I, Nelson PS, Zhang M, Dash R, Fisher PB, Plymate SR, Wu JD. (2011). IL-6 promotes prostate tumorigenesis and progression through autocrine cross-activation of IGF-IR. Oncogene 30: 2345-2355
37. Schneider CA, Rasband WS, Eliceiri KW. (2012). NIH Image to ImageJ: 25 years of image analysis. Nat Methods 9: 671-675
38. Sciarra A, Mariotti G, Salciccia S, Autran Gomez A, Monti S, Toscano V, Di Silverio F. (2008). Prostate growth and inflammation. J Steroid Biochem Mol Biol 108: 254-260
39. Stock D, Groome PA, Siemens DR. (2008). Inflammation and prostate cancer: a future target for prevention and therapy?. Urol Clin North Am 35: 117-130vii
40. Suzuki T, Inoue A, Miki Y, Moriya T, Akahira J, Ishida T, Hirakawa H, Yamaguchi Y, Hayashi S, Sasano H. (2007). Early growth responsive gene 3 in human breast carcinoma: a regulator of estrogen-meditated invasion and a potent prognostic factor. Endocr Relat Cancer 14: 279-292
41. Swirnoff AH, Milbrandt J. (1995). DNA-binding specificity of NGFI-A and related zinc finger transcription factors. Mol Cell Biol 15: 2275-2287
42. Taniguchi K, Karin M. (2014). IL-6 and related cytokines as the critical lynchpins between inflammation and cancer. Semin Immunol 26: 54-74
43. Tomlins SA, Mehra R, Rhodes DR, Cao X, Wang L, Dhanasekaran SM, Kalyana-Sundaram S, Wei JT, Rubin MA, Pienta KJ, Shah RB, Chinnaiyan AM. (2007). Integrative molecular concept modeling of prostate cancer progression. Nat Genet 39: 41-51
44. Wang XD, Reeves K, Luo FR, Xu LA, Lee F, Clark E, Huang F. (2007). Identification of candidate predictive and surrogate molecular markers for dasatinib in prostate cancer: rationale for patient selection and efficacy monitoring. Genome Biol 8: R255
45. Wang Y, Xia XQ, Jia Z, Sawyers A, Yao H, Wang-Rodriquez J, Mercola D, McClelland M. (2010). In silico estimates of tissue components in surgical samples based on expression profiling data. Cancer Res 70: 6448
46. Waugh DJ, Wilson C. (2008). The interleukin-8 pathway in cancer. Clin Cancer Res 14: 6735-6741
47. Welch DR, Schissel DJ, Howrey RP, Aeed PA. (1989). Tumor-elicited polymorphonuclear cells, in contrast to "normal" circulating polymorphonuclear cells, stimulate invasive and metastatic potentials of rat mammary adenocarcinoma cells. Proc Natl Acad Sci USA 86: 5859-5863
48. Wieland GD, Nehmann N, Muller D, Eibel H, Siebenlist U, Suhnel J, Zipfel PF, Skerka C. (2005). Early growth response proteins EGR-4 and EGR-3 interact with immune inflammatory mediators NF-kappaB p50 and p65. J Cell Sci 118: 3203-3212